RE:Don't expect MuchIf corporate management and share structure is the impediment, then we need to do a JV with big pharmacy (Big P) that is structured to benefit both parties, protect both parties, and maximize efficient operation of the JV.
Scope: PMN 310 development and commercialization
Big P contribution: $20M for Phase 1 funding plus a commitment for Phase 2-3 funding contingent on quantifiable technical and market analysis metrics.
Big P gains: 10% ownership of ProMIS. 80% of JV earnings. Control of JV management.
PMN contribution: Exclusive license for PMN310 in humanized form, as well as future vaccine formats. IND enabling work for Phase 1and technical support for all material issues pertaining to PMN 310.
PMN gains: 10% of JV revenues (licensing fee) plus 20% of earnings.
So, how would that work out if said JV captured $10B per year in sales? PMN would get $1B off the top. Assuming a profit margin of 25%, Big P would get about $2B in earnings and PMN would get another $500m.